Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 5/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 5/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.35 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | SRC | P12931 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6657600 | 0.89 | CYP11B1 (0.43) | CYP11B2CYP11B1CYP19A1SLC22A12CYP17A1 | |
| SCHEMBL6656515 | 0.86 | CYP17A1 (0.47) | CYP17A1TNFCYP1A2HTR6 | |
| SCHEMBL6847479 | 0.83 | CYP17A1 (0.40) | CYP11B2CYP19A1CYP17A1CYP1A2 | |
| SCHEMBL6661647 | 0.82 | MAPK14 (0.44) | CYP11B2CYP11B1CYP17A1CYP1A2 | |
| SCHEMBL6845971 | 0.82 | SETD7 (0.41) | SLC22A12CYP17A1CYP1A2HTR6 | |
| SCHEMBL6840591 | 0.80 | CYP17A1 (0.52) | CYP17A1CYP1A2 | |
| SCHEMBL6844416 | 0.78 | CDC7 (0.41) | CYP17A1CYP1A2 | |
| SCHEMBL6845459 | 0.78 | DHODH (0.41) | CYP11B2CYP11B1SLC22A12CYP17A1CYP1A2 | |
| SCHEMBL6659149 | 0.77 | CYP11B2 (0.49) | CYP11B2CYP11B1CYP19A1CYP17A1CYP1A2 | |
| SCHEMBL6659801 | 0.77 | CYP1A2 (0.40) | CYP11B2CYP11B1CYP19A1SLC22A12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | BAYER PHARMACEUTICALS CORPORATION | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040236110-A1 | Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors | CYP17A1, IDO1, CYP21A2 | CYP11B2 53/4885CYP11B1 30/4885CYP19A1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.